Mycoplasma Testing Market in terms of revenue was estimated to be worth $689 million in 2020 and is poised to reach $1,095 million by 2025, growing at a CAGR of 9.7% from 2020 to 2025. The global market’s growth is driven by factors such as the growing concerns over cell culture contamination, growth in the pharmaceutical and biotechnology industries, and rising pharmaceutical R & D activities and investments.
The global mycoplasma testing markets growth is driven by factors such as the growing concerns over cell culture contamination, growth in the pharmaceutical and biotechnology industries, and rising pharmaceutical R & D activities and investments.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=136509856
Browse in-depth TOC on “Mycoplasma Testing Market”
111 – Tables
37 – Figures
154 – Pages
Key Market Players
The major players operating in this market are Thermo Fisher Scientific, Inc. (US), Charles River Laboratories International, Inc. (US), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), American Type Culture Collection (US), Bionique Testing Laboratories, Inc. (US), InvivoGen (US), PromoCell GmbH (Germany), Biological Industries Israel Beit Haemek Ltd. (Israel), Creative Bioarray (US), Mycoplasma Experience (UK), Norgen Biotek Corp. (Canada), Agilent Technologies (US), Biotools B & M Labs, S.A. (Spain), Eurofins Scientific (Luxembourg), GeneCopoeia, Inc. (US), GenBio (Canada), Minerva Biolabs GmbH (Germany), Meridian Bioscience, Inc. (US), Sartorius AG (Germany), Savyon Diagnostics (Israel), Nelson Laboratories Fairfield, Inc. (US), Clongen Laboratories, LLC (US), and ScienCell Research Laboratories, Inc. (Canada).
Drivers: Growing concerns over cell culture contamination
Cell culture contamination is the most common problem encountered in cell culture laboratories. Cell culture contaminants are divided into two main categories, namely, chemical contaminants and biological contaminants. Chemical contaminants include impurities in media, sera, water, endotoxins, plasticizers, and detergents, while biological contaminants include bacteria, mold, yeast, viruses, and mycoplasma as cross-contamination by other cell lines. For contamination detection, various tests, including mycoplasma testing, are used.
Opportunities: Globalization of clinical trials and R&D and harmonization of regulations resulting in increased outsourcing
The primary reasons pharmaceutical and biopharmaceutical companies are opting for outsourcing clinical trials and R&D are cost efficiency, easy patient recruitment, reduction in operating costs, and less-stringent regulatory frameworks than the US and Western Europe. Besides reducing costs, sponsors attribute improved quality and reduction in the time to market as major drivers for outsourcing their business functions to CROs, CDMOs, and CMOs. Hence, many pharmaceutical and biotechnology companies and academic institutes opt to outsource functions like manufacturing, clinical trial management, R&D, and drug discovery to CROs.
Challenges: High degree of consolidation acts as an entry barrier for new entrants
The top players in this market are large and well-established and enjoy a high degree of brand loyalty. New entrants in this market compete with existing players and set themselves apart by developing innovative product offerings. The high degree of consolidation acts as a major entry barrier for new entrants, which in turn, is expected to restrict investments and thus slow down the growth potential of this market.
Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=136509856
Cell line testing segment accounted for the largest share in the mycoplasma testing market, by application.
Based on application, the global market is segmented into cell line testing, virus testing, and end-of-production cell testing. In 2019, the cell line testing segment accounted for the largest share of this market. Factors such as the rapid growth in the biopharmaceutical industry and the increasing demand for monoclonal antibodies drive this market segment’s growth.
North America is the largest regional market for mycoplasma testing market
The global mycoplasma testing market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest share of the global mycoplasma testing market. The large share can be attributed primarily to the growth in biotechnology and pharmaceutical industries, the high adoption rate of novel technologies, and the large number of life science research studies conducted in this region.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=136509856
Recent Developments:
- In July 2020, Roche Diagnostics launched Cobas 6800, a fully automated system in India.
- In July 2020, Creative Bioarray launched a full range of cell-based services
- In January 2020, Charles River Laboratories (US) acquired HemaCare Corporation (US)
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/mycoplasma-testing-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/mycoplasma-testing.asp
Related Report:
